Peptide News Digest

#Who

3 stories

Clinical Trials · View digest

26th International AIDS Conference (AIDS 2026) Day 2 on Tuesday July 28, 2026 in Rio de Janeiro Includes World Health Organization (WHO) Interactive Workshop 14:30-16:30 BRT in Room 101C on Practical Approaches to Sustaining HIV, Tuberculosis (TB), Viral Hepatitis, and Sexually Transmitted Infection (STI) Services for Key Populations Through Integrated Primary Health Care, Plus European AIDS Treatment Group (EATG) Poster Sessions on the SCOPE, Belong, and RBDCOV Projects, and Clinton Health Access Initiative (CHAI) Cost-Effectiveness Presentation on Dual HIV/Syphilis and Triplex HIV/Syphilis/HBV Rapid Diagnostic Testing Among Pregnant Women in Kenya and South Africa (15:27-15:35 BRT)

The 26th International AIDS Conference (AIDS 2026) Day 2 continues Tuesday July 28, 2026 at Riocentro in Rio de Janeiro, Brazil. Key Tuesday programming includes: the World Health Organization (WHO) interactive workshop in Room 101C from 14:30-16:30 BRT on practical approaches to sustaining HIV, tuberculosis (TB), viral hepatitis, and sexually transmitted infection (STI) services for key populations through integrated primary health care (particularly timely following the UNAIDS 'United to End AIDS' report Monday documenting 2025 HIV funding cuts); the European AIDS Treatment Group (EATG) poster sessions Tuesday and Wednesday on the SCOPE, Belong, and RBDCOV research projects; the Clinton Health Access Initiative (CHAI) cost-effectiveness presentation on dual HIV/syphilis and triplex HIV/syphilis/HBV rapid diagnostic testing among pregnant women in Kenya and South Africa (15:27-15:35 BRT); and the ViiV Healthcare peer-support-in-HIV-care session from 12:00-13:00 BRT. All abstracts (oral, poster, e-poster, and late-breaker) became available on-demand on Monday July 27 at 14:00 BRT for registered delegates, with on-demand session recordings available 4-12 hours after they take place. The main peptide-adjacent industry late-breaker (Gilead-Merck ISLEND-1 and ISLEND-2 detailed data) is scheduled for Wednesday July 29.

Clinical Trials · View digest

26th International AIDS Conference (AIDS 2026) Main Conference Opens Monday July 27, 2026 at Riocentro in Rio de Janeiro Brazil (Opening Ceremony 15:00-16:30 Local Time in the Global Village) With Release of the UNAIDS 'United to End AIDS' 2025 Data Report Documenting the Severity of 2025 HIV Funding Cuts and the WHO's First Global Mid-Term Assessment of Progress Under the Global Health Sector Strategies on HIV Viral Hepatitis and Sexually Transmitted Infections Marking the Halfway Point to the 2030 Targets — Peptide-Adjacent HIV Modality Content This Week Includes Gilead Sciences Lenacapavir PURPOSE 1 and PURPOSE 2 Long-Term Extension Data and Gilead-Merck Islatravir/Lenacapavir Phase 3 ISLEND-1 and ISLEND-2 Late-Breaker Wednesday July 29

The 26th International AIDS Conference (AIDS 2026) main conference opened Monday July 27, 2026 at Riocentro in Rio de Janeiro, Brazil. The opening ceremony ran 15:00-16:30 local time in the Global Village. UNAIDS released its 'United to End AIDS' 2025 data report on the opening day, documenting the severity of 2025 HIV funding cuts and their impact on HIV prevention, community services, key populations, and the sustainability of the global AIDS response. The WHO launched its first global mid-term assessment of progress under the Global Health Sector Strategies on HIV, viral hepatitis, and sexually transmitted infections, marking the halfway point to the 2030 targets and providing a comprehensive overview of where the world stands on the SDG 3.3 targets. Peptide-adjacent HIV modality content this week includes Gilead Sciences's twice-yearly lenacapavir (first-in-class HIV capsid inhibitor) PURPOSE 1 and PURPOSE 2 long-term extension data and the Gilead-Merck once-weekly oral islatravir/lenacapavir Phase 3 ISLEND-1 and ISLEND-2 detailed data late-breaker scheduled for Wednesday July 29. Merck plans separate presentations across daily, weekly, and monthly HIV treatment and prevention pipeline including alimatravir (MK-8527), the investigational once-monthly oral HIV prevention pill licensed July 24 to Aspen Pharmacare and six other generic manufacturers for 129 low- and middle-income countries.

Research · View digest

BARNARDS II Study at ESCMID: WHO First-Line Antibiotics Cover Only 1 in 4 Neonatal Sepsis Cases

Findings from the Oxford-led BARNARDS II study presented at ESCMID Global 2026 showed WHO-recommended ampicillin plus gentamicin first-line therapy is likely effective for only 1 in 4 neonatal sepsis infections in low- and middle-income countries. Data were collected across 13 tertiary neonatal units in Pakistan, Bangladesh, and Nigeria from February 2024 to October 2025, intensifying the case for AMR-driven peptide alternatives.